Lucidome Bio
- Company typePrivate
- Founded2024
- HeadquartersWellington, New Zealand
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Lucidome Bio firmographics
Firmographics- Name
- Lucidome Bio
- Legal name
- Lucidome Bio
- Website
- https://lucidomebio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Lucidome Bio industry classification
Industry- Product category
- Livestock Vaccines
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Veterinary Vaccines (Biologics) (HLAMAEAL)
- akta.pro secondary industries
- Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Lucidome Bio is headquartered
LocationHeadquarters
- HQ city
- Wellington
- HQ country
- New Zealand
- HQ region
- Oceania
Offices1 record
Markets served
Lucidome Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Methane-reducing vaccine for livestock: Pre-revenue company in R&D phase. Plans to commercialize a methane-reducing vaccine for ruminant animals. The company aims to get approved vaccines into the hands of farmers within five years, with potential licensing opportunities to global animal health companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Lucidome Bio product offering
Product offeringCore offering
Lucidome Bio is developing a single methane-reducing vaccine for ruminant livestock (cattle and sheep). The vaccine trains the animal's immune system to produce antibodies in saliva that bind to methane-producing microbes (methanogens) in the rumen, suppressing methanogen growth and reducing methane emissions while maintaining animal health and productivity. The product is currently in R&D with field trials underway, targeting commercial availability within approximately five years.
Product overview
Lucidome Bio is developing a single core product: a methane-reducing vaccine for ruminant livestock (cattle and other grazing animals). The vaccine triggers the animal's immune system to produce antibodies in saliva that suppress methanogens in the rumen, reducing methane emissions while boosting productivity. The company is focused on accelerating development through advanced digital tools including AI-assisted biological modelling, genomic analysis, and bioinformatics to identify and validate vaccine targets. The vaccine is designed to be safe, scalable, and affordable for pasture-based farming systems worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Methane Reducing Vaccine A vaccine designed to train the immune system of ruminant animals (cattle, sheep, and other grazing livestock) to produce antibodies in saliva that suppress methane-producing microbes (methanogens) in the rumen. The vaccine targets methanogen surface proteins, reducing methanogen growth and methane emissions without affecting animal health or digestion. It is being developed for pasture-based and mixed farming systems where feed additives are ineffective, with global applicability supported by demonstrated consistency of methanogen populations worldwide.
Quantifiable outcome
- Antibodies in saliva sufficient to coat all methanogens in the rumen (10,000+ antibody molecules per methanogen cell)
- +2 more outcomes
Companies that use Lucidome Bio
Customer profileSegments1 record
Ideal customer profiles2 records
Lucidome Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Lucidome Bio partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- AgResearchcoreCritical research partner providing scientific expertise. AgResearch scientists are seconded to Lucidome Bio and provide access to research facilities. The methane vaccine research has been pioneered by AgResearch scientists for over 15 years.
- The Pirbright InstitutecoreCollaborating on methane vaccine research. Part of international consortium funded by Bezos Earth Fund. Provides expertise in livestock vaccine development alongside Royal Veterinary College.
- University of MelbourneminorAcademic partner collaborating on vaccine development research. Dr Peter Janssen previously held academic position at Department of Microbiology and Immunology.
- University of WellingtonminorAcademic partner that collaborated with AgResearch on testing efficacy of adjuvants for veterinary use.
- University of Technology Sydney (UTS)minorAcademic partner collaborating on vaccine development research.
- Royal Veterinary CollegeminorPart of international consortium with Pirbright Institute and AgResearch funded by Bezos Earth Fund for methane vaccine research.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Lucidome Bio competitors and assessment
Company assessmentDirect peers
- ArkeaBio: ArkeaBio is developing a methane-reducing vaccine for cattle and other ruminants, making it the closest direct competitor to Lucidome Bio. Both companies pursue antibody-based vaccine approaches targeting rumen methanogens, addressing the same customer base of livestock producers under climate-driven demand.
- Zelp (Zero Emissions Livestock Project): Zelp develops methane-mitigation technology for cattle, including wearable devices and feed-related approaches to reduce enteric emissions. It targets the same dairy and beef producers motivated by methane reduction that Lucidome Bio is addressing.
- CH4 Global: CH4 Global commercializes Asparagopsis seaweed-based feed supplements to reduce enteric methane in cattle. It is a leading direct competitor pursuing a feed-additive pathway to the same methane-reduction outcome, serving beef and dairy producers globally.
- Symbrosia: Symbrosia uses seaweed (Asparagopsis) as a feed additive to reduce livestock methane emissions. It competes with Lucidome Bio for the same farmer/customer dollars aimed at reducing enteric methane, although via a different technical approach.
Emerging players
- Mootral: Mootral develops feed-additive and natural-product based solutions for enteric methane reduction in cattle. It overlaps with Lucidome Bio's target market (methane-conscious dairy and beef producers) but uses a different technical mechanism.
Regional players
- Sea Forest: Sea Forest is an Australian company producing Asparagopsis-based feed supplements for livestock methane reduction. It competes in adjacent geographies (primarily Australia) with a similar end-customer value proposition to Lucidome Bio's vaccine.
Broad incumbents
- Elanco Animal Health: Elanco is a large global animal health company offering vaccines, pharmaceuticals, and sustainability solutions for livestock. It is a potential licensee or strategic partner for Lucidome Bio, given its established global veterinary distribution and growing sustainability portfolio.
- Zoetis: Zoetis is the world's largest animal health company with deep livestock vaccine and pharmaceutical capabilities. As a broad incumbent, it is a likely candidate for licensing Lucidome Bio's vaccine technology and reaching Lucidome Bio's target customer base globally.
- Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health division is a global leader in livestock vaccines and therapeutics. It represents a likely strategic/licensing partner for Lucidome Bio, with established channels to deliver novel vaccines to the same ruminant producers Lucidome Bio targets.
- dsm-firmenich: dsm-firmenich is a major animal nutrition and health company developing feed additives including methane-reduction solutions (e.g., Bovaer/3-NOP). It is comparable to Lucidome Bio as an adjacent incumbent working on enteric methane reduction through a feed-additive route.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Lucidome Bio social profiles
Digital presenceLucidome Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucidome Bio leadership team
Management profileNumber of profiles
Profiles8 records
Lucidome Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucidome Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucidome Bio
What does Lucidome Bio do?
Lucidome Bio is developing a single methane-reducing vaccine for ruminant livestock (cattle and sheep). The vaccine trains the animal's immune system to produce antibodies in saliva that bind to methane-producing microbes (methanogens) in the rumen, suppressing methanogen growth and reducing methane emissions while maintaining animal health and productivity. The product is currently in R&D with field trials underway, targeting commercial availability within approximately five years.
Is Lucidome Bio a public or private company?
Lucidome Bio is a private company. It is classified as corporate owned and is currently operating.
When was Lucidome Bio founded?
Lucidome Bio was founded in 2024. It employs 1 to 10 people.
Where is Lucidome Bio based?
Lucidome Bio is headquartered in Wellington, New Zealand, in the Oceania region.
How does Lucidome Bio make money?
One revenue line is on record: methane-reducing vaccine for livestock.
Who are Lucidome Bio's main competitors?
Direct peers on record are ArkeaBio, Zelp (Zero Emissions Livestock Project), CH4 Global and Symbrosia. Mootral is listed as an emerging player. Sea Forest is listed as a regional player. Broad incumbents are Elanco Animal Health, Zoetis, Boehringer Ingelheim Animal Health and dsm-firmenich.
Does Lucidome Bio have an API?
No public API is recorded for Lucidome Bio.
What industry is Lucidome Bio in?
Lucidome Bio's product category is Livestock Vaccines. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAB, Livestock Vaccines (Cattle, Swine, Sheep & Goats). Its SIC code is 2836.